Eric L Sievers
Overview
Explore the profile of Eric L Sievers including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
3586
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sievers B, Sievers R, Sievers E
Open Forum Infect Dis
. 2023 Jun;
10(6):ofad302.
PMID: 37383252
Children living in war-torn and geographically remote regions often die from measles due to undervaccination. Protective community immunity could be safely improved through the comprehensive use of small, inexpensive, easy-to-use,...
2.
Sievers B, Sievers R, Sievers E
J Virus Erad
. 2022 Dec;
8(4):100310.
PMID: 36578361
Measles-we've become inured to its cruel, insidious impact as it kills over 100,000 children yearly because of suboptimal vaccination coverage. It does not have to be this way. A familiar,...
3.
Kruglov O, Johnson L, Minic A, Jordan K, Uger R, Wong M, et al.
Cancer Immunol Immunother
. 2021 Sep;
71(4):919-932.
PMID: 34519839
CD47 is frequently overexpressed on tumor cells and is an attractive therapeutic target. The mechanism by which anti-CD47 immunotherapy eliminates cutaneous lymphoma has not been explored. We utilized CRISPR/Cas-9 CD47...
4.
Ansell S, Maris M, Lesokhin A, Chen R, Flinn I, Sawas A, et al.
Clin Cancer Res
. 2021 Jan;
27(8):2190-2199.
PMID: 33451977
Purpose: TTI-621 (SIRPα-IgG1 Fc) is a novel checkpoint inhibitor that activates antitumor activity by blocking the CD47 "don't eat me" signal. This first-in-human phase I study (NCT02663518) evaluated the safety...
5.
Johnson L, Banerjee S, Kruglov O, Nielsen Viller N, Horwitz S, Lesokhin A, et al.
Blood Adv
. 2019 Apr;
3(7):1145-1153.
PMID: 30962222
Sézary syndrome (SS), the leukemic variant of cutaneous T-cell lymphoma, has limited treatment options and rare occurrences of long-term remission, thus warranting research into new treatment approaches. CD47 has emerged...
6.
Petrova P, Nielsen Viller N, Wong M, Pang X, Lin G, Dodge K, et al.
Clin Cancer Res
. 2016 Nov;
23(4):1068-1079.
PMID: 27856600
The ubiquitously expressed transmembrane glycoprotein CD47 delivers an anti-phagocytic (do not eat) signal by binding signal-regulatory protein α (SIRPα) on macrophages. CD47 is overexpressed in cancer cells and its expression...
7.
Gopal A, Pro B, Connors J, Younes A, Engert A, Shustov A, et al.
Clin Trials
. 2016 May;
13(5):545-54.
PMID: 27154912
Background: Independent central review of clinical imaging remains the standard for oncology clinical trials with registration potential. A limited independent central review strategy has been proposed for solid tumor trials...
8.
Moskowitz C, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi M, et al.
Lancet
. 2015 Mar;
385(9980):1853-62.
PMID: 25796459
Background: High-dose therapy followed by autologous stem-cell transplantation is standard of care for patients with relapsed or primary refractory Hodgkin's lymphoma. Roughly 50% of patients might be cured after autologous...
9.
Gopal A, Chen R, Smith S, Ansell S, Rosenblatt J, Savage K, et al.
Blood
. 2014 Dec;
125(8):1236-43.
PMID: 25533035
We present response and survival outcomes of a pivotal phase 2 trial of the antibody-drug conjugate brentuximab vedotin in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant (N...
10.
Sievers E, Senter P
Annu Rev Med
. 2012 Oct;
64:15-29.
PMID: 23043493
An antibody-drug conjugate (ADC) provides the possibility of selectively ablating cancer cells by combining the specificity of a monoclonal antibody (mAb) for a target antigen with the delivery of a...